SELLAS Life Sciences Group

SELLAS funds its operations entirely through equity raises on the Nasdaq public market, as it is a publicly traded biotechnology company. The firm has periodic follow-on public offerings and registered direct offerings to extend its cash runway through critical clinical milestones. It does not operate as a venture capital firm, a family office, or a fund that accepts limited partner commitments.

Galinpepimut-S (GPS) is a peptide-based cancer vaccine that targets the Wilms' Tumor 1 protein, which is overexpressed in acute myeloid leukemia and other cancers. The vaccine trains the patient's immune system to recognize and kill WT1-positive cancer cells. The ongoing Phase 3 REGAL trial is evaluating GPS as a maintenance therapy for AML patients in second complete remission, a population with no approved maintenance options.

In May 2024, SELLAS terminated its exclusive license for the CDK9 inhibitor GFH009, returning rights to the Chinese originator GenFleet Therapeutics. The firm stated the move was a capital-allocation decision to focus all resources on completing the Phase 3 REGAL trial for its lead asset, galinpepimut-S, ahead of the expected interim analysis. The GFH009 program had enrolled patients in Phase 1 dose-escalation studies in the U.S. and China prior to termination (per press release, 2024).

Beyond acute myeloid leukemia, SELLAS has clinical data from its second candidate, nelipepimut-S, in non-small cell lung cancer, advanced breast cancer, and other solid tumors overexpressing the HER2/neu oncoprotein. NPS completed Phase 2 trials in breast cancer with promising results in certain patient subsets, though the firm has prioritized GPS for near-term regulatory strategy. The company's earlier preclinical work also studied its WT1 vaccine platform in mesothelioma and multiple myeloma.

SELLAS has not publicly disclosed active partnership negotiations, but its public statements consistently describe the goal of advancing GPS to regulatory approval and commercialization, either independently or through a strategic partnership. The orphan-drug and fast-track designations held by GPS for AML make it a logical licensing target for larger oncology-focused pharmaceutical firms, particularly if the Phase 3 REGAL trial meets its primary endpoint of overall survival.

Unlike oral hypomethylating agents or targeted FLT3 inhibitors used in AML maintenance, GPS is a vaccine designed to produce a durable T-cell immune response against residual WT1-positive cancer cells and leukemia stem cells. No WT1-targeting vaccine is currently approved, placing SELLAS in a first-to-market position if the Phase 3 REGAL trial succeeds. GPS has received FDA fast-track designation and orphan drug designation from both the FDA and the European Medicines Agency.

President and CEO Angelos Stergiou is the primary strategic decision-maker and public face of the firm. Stergiou holds both an MD and a doctorate in tumor immunology, and he has led the company's development of its WT1 vaccine platform since inception. The product-level decisions — trial design, regulatory pathway, and capital allocation among pipeline assets — are ultimately his, approved by a board of directors typical of a public reporting company.